Literature DB >> 16006513

Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase.

Ji Luo1, Cassandra L Sobkiw, Nicole M Logsdon, John M Watt, Sabina Signoretti, Fionnuala O'Connell, Eyoung Shin, Youngju Shim, Lily Pao, Benjamin G Neel, Ronald A Depinho, Massimo Loda, Lewis C Cantley.   

Abstract

Mice with heterozygous deletion of the PTEN tumor suppressor gene develop a range of epithelial neoplasia as well as lymphoid hyperplasia. Previous studies suggest that PTEN suppresses tumor formation by acting as a phosphoinositide phosphatase to limit signaling by phosphoinositide 3-kinase (PI3K). Here, we examined the effect of deleting various regulatory subunits of PI3K (p85alpha and p85beta) on epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice. Interestingly, we found the loss of one p85alpha allele with or without the loss of p85beta led to increased incidence of intestinal polyps. Signaling downstream of PI3K was enhanced in the PTEN+/-p85alpha+/-p85beta-/- polyps, as judged by an increased fraction of both cells with cytoplasmic staining of the transcription factor FKHR and cells with positive staining for the proliferation marker Ki-67. In contrast, the incidence of prostate intraepithelial neoplasia was not significantly altered in PTEN+/- mice heterozygous for p85alpha or null for p85beta, whereas the fraction of proliferating cells in prostate intraepithelial neoplasia was reduced in mice lacking p85beta. Finally, there was no significant change in T lymphocyte hyperplasia in the PTEN+/- mice with various p85 deletions, although anti-CD3-stimulated AKT activation was somewhat reduced in the p85alpha+/- background. These results indicate that decreasing the levels of different p85 regulatory subunits can result in enhanced PI3K signaling in some tissues and decreased PI3K signaling in others, supporting the model that, although p85 proteins are essential for class I(A) PI3K signaling, they can function as inhibitors of PI3K signaling in some tissues and thus suppress tumor formation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16006513      PMCID: PMC1174923          DOI: 10.1073/pnas.0504378102

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice.

Authors:  Saskia M Brachmann; Kohjiro Ueki; Jeffrey A Engelman; Ronald C Kahn; Lewis C Cantley
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

2.  Impaired Fas response and autoimmunity in Pten+/- mice.

Authors:  A Di Cristofano; P Kotsi; Y F Peng; C Cordon-Cardo; K B Elkon; P P Pandolfi
Journal:  Science       Date:  1999-09-24       Impact factor: 47.728

3.  Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase.

Authors:  L Bi; I Okabe; D J Bernard; A Wynshaw-Boris; R L Nussbaum
Journal:  J Biol Chem       Date:  1999-04-16       Impact factor: 5.157

4.  PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.

Authors:  Jong Woo Lee; Young Hwa Soung; Su Young Kim; Hae Woo Lee; Won Sang Park; Suk Woo Nam; Sang Ho Kim; Jung Young Lee; Nam Jin Yoo; Sug Hyung Lee
Journal:  Oncogene       Date:  2005-02-17       Impact factor: 9.867

5.  Mutation of the PIK3CA gene in ovarian and breast cancer.

Authors:  Ian G Campbell; Sarah E Russell; David Y H Choong; Karen G Montgomery; Marianne L Ciavarella; Christine S F Hooi; Briony E Cristiano; Richard B Pearson; Wayne A Phillips
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

6.  Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.

Authors:  Sohye Kang; Andreas G Bader; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-12       Impact factor: 11.205

7.  Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems.

Authors:  K Podsypanina; L H Ellenson; A Nemes; J Gu; M Tamura; K M Yamada; C Cordon-Cardo; G Catoretti; P E Fisher; R Parsons
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

8.  Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase.

Authors:  Y Terauchi; Y Tsuji; S Satoh; H Minoura; K Murakami; A Okuno; K Inukai; T Asano; Y Kaburagi; K Ueki; H Nakajima; T Hanafusa; Y Matsuzawa; H Sekihara; Y Yin; J C Barrett; H Oda; T Ishikawa; Y Akanuma; I Komuro; M Suzuki; K Yamamura; T Kodama; H Suzuki; K Yamamura; T Kodama; H Suzuki; S Koyasu; S Aizawa; K Tobe; Y Fukui; Y Yazaki; T Kadowaki
Journal:  Nat Genet       Date:  1999-02       Impact factor: 38.330

9.  High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice.

Authors:  A Suzuki; J L de la Pompa; V Stambolic; A J Elia; T Sasaki; I del Barco Barrantes; A Ho; A Wakeham; A Itie; W Khoo; M Fukumoto; T W Mak
Journal:  Curr Biol       Date:  1998-10-22       Impact factor: 10.834

Review 10.  Phosphoinositide kinases.

Authors:  D A Fruman; R E Meyers; L C Cantley
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

View more
  25 in total

1.  The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling.

Authors:  Cullen M Taniguchi; Jonathon Winnay; Tatsuya Kondo; Roderick T Bronson; Alexander R Guimaraes; José O Alemán; Ji Luo; Gregory Stephanopoulos; Ralph Weissleder; Lewis C Cantley; C Ronald Kahn
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

2.  Phosphoinositide 3-kinase regulatory subunit p85alpha suppresses insulin action via positive regulation of PTEN.

Authors:  Cullen M Taniguchi; Thien T Tran; Tatsuya Kondo; Ji Luo; Kohjiro Ueki; Lewis C Cantley; C Ronald Kahn
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-31       Impact factor: 11.205

3.  Phosphorylation of ErbB4 on Tyr1056 is critical for inhibition of colony formation by prostate tumor cell lines.

Authors:  Richard M Gallo; Ianthe Bryant; Rachael Fry; Eric E Williams; David J Riese
Journal:  Biochem Biophys Res Commun       Date:  2006-08-18       Impact factor: 3.575

Review 4.  The PI3K Pathway in Human Disease.

Authors:  David A Fruman; Honyin Chiu; Benjamin D Hopkins; Shubha Bagrodia; Lewis C Cantley; Robert T Abraham
Journal:  Cell       Date:  2017-08-10       Impact factor: 41.582

5.  p85β phosphoinositide 3-kinase subunit regulates tumor progression.

Authors:  Isabel Cortés; Jesús Sánchez-Ruíz; Susana Zuluaga; Vincenzo Calvanese; Miriam Marqués; Carmen Hernández; Teresa Rivera; Leonor Kremer; Ana González-García; Ana C Carrera
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-25       Impact factor: 11.205

6.  p85 protein expression is associated with poor survival in HER2-positive patients with advanced breast cancer treated with trastuzumab.

Authors:  Kitty Pavlakis; Mattheos Bobos; Anna Batistatou; Vassiliki Kotoula; Anastasia G Eleftheraki; Anastasios Stofas; Eleni Timotheadou; George Pentheroudakis; Amanda Psyrri; Angelos Koutras; Dimitrios Pectasides; Pavlos Papakostas; Evangelia Razis; Christos Christodoulou; Konstantine T Kalogeras; George Fountzilas
Journal:  Pathol Oncol Res       Date:  2014-08-08       Impact factor: 3.201

7.  ERK-mediated NGF signaling in the rat septo-hippocampal pathway diminishes with age.

Authors:  Brice J Williams; Heather A Bimonte-Nelson; Ann-Charlotte Granholm-Bentley
Journal:  Psychopharmacology (Berl)       Date:  2006-08-17       Impact factor: 4.530

8.  Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase.

Authors:  Ryaz B Chagpar; Philip H Links; M Chris Pastor; Levi A Furber; Andrea D Hawrysh; M Dean Chamberlain; Deborah H Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-08       Impact factor: 11.205

9.  Irs2 inactivation suppresses tumor progression in Pten+/- mice.

Authors:  Matthias Szabolcs; Megan Keniry; Laura Simpson; Latarsha J Reid; Susan Koujak; Sarah C Schiff; Giselle Davidian; Scott Licata; Sofia Gruvberger-Saal; Vundavalli V V S Murty; Subhadra Nandula; Argiris Efstratiadis; Jake A Kushner; Morris F White; Ramon Parsons
Journal:  Am J Pathol       Date:  2008-12-18       Impact factor: 4.307

Review 10.  Immunological considerations of modern animal models of malignant primary brain tumors.

Authors:  Michael E Sughrue; Isaac Yang; Ari J Kane; Martin J Rutkowski; Shanna Fang; C David James; Andrew T Parsa
Journal:  J Transl Med       Date:  2009-10-08       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.